These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 20118001)

  • 1. [Dual-color/dual-fusion interphase fluorescence in situ hybridization probe for monitoring tumor load during imatinib therapy for chronic myeloid leukemia].
    DU QF; Zhang S; Liu XL; Meng FY
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Jan; 30(1):123-5. PubMed ID: 20118001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of dual color-dual fusion translocation fluorescence in situ hybridization in the detection of bcr/abl fusion gene.
    Wu B; Zhou S; Song L; Liu X
    Zhonghua Zhong Liu Za Zhi; 2002 Jul; 24(4):364-6. PubMed ID: 12408765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.
    Frater JL; Tallman MS; Variakojis D; Druker BJ; Resta D; Riley MB; Hrisinko MA; Peterson LC
    Am J Clin Pathol; 2003 Jun; 119(6):833-41. PubMed ID: 12817431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytogenetic and fluorescence in situ hybridization monitoring in Ph+ Chronic Myeloid Leukemia patients treated with imatinib mesylate.
    Fugazza G; Miglino M; Bruzzone R; Quintino S; Gatti AM; Grasso R; Gobbi M; Frassoni F; Sessarego M
    J Exp Clin Cancer Res; 2004 Jun; 23(2):295-9. PubMed ID: 15354415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. e6a2 BCR/ABL1 fusion with cryptic der(9)t(9;22) deletions in a patient with chronic myeloid leukemia.
    Roti G; La Starza R; Gorello P; Gottardi E; Crescenzi B; Martelli MF; Mecucci C
    Haematologica; 2005 Aug; 90(8):1139-41. PubMed ID: 16079118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A two-color BCR-ABL probe that greatly reduces the false positive and false negative rates for fluorescence in situ hybridization in chronic myeloid leukemia.
    Grand FH; Chase A; Iqbal S; Nguyen DX; Lewis JL; Marley SB; Davidson RJ; Goldman JM; Gordon MY
    Genes Chromosomes Cancer; 1998 Oct; 23(2):109-15. PubMed ID: 9739013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FISH for BCR-ABL on interphases of peripheral blood neutrophils but not of unselected white cells correlates with bone marrow cytogenetics in CML patients treated with imatinib.
    Reinhold U; Hennig E; Leiblein S; Niederwieser D; Deininger MW
    Leukemia; 2003 Oct; 17(10):1925-9. PubMed ID: 14513039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic phase of ETV6-ABL1 positive CML responds to imatinib.
    Kawamata N; Dashti A; Lu D; Miller B; Koeffler HP; Schreck R; Moore S; Ogawa S
    Genes Chromosomes Cancer; 2008 Oct; 47(10):919-21. PubMed ID: 18615681
    [No Abstract]   [Full Text] [Related]  

  • 9. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].
    Qin YZ; Ruan GR; Liu YR; Li JL; Fu JY; Wang H; Chang Y; Jiang B; Jiang Q; Jiang H; Qiu JY; Chen SS; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):1-5. PubMed ID: 15946498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib.
    Gadzicki D; von Neuhoff N; Steinemann D; Just M; Büsche G; Kreipe H; Wilkens L; Schlegelberger B
    Cancer Genet Cytogenet; 2005 Jun; 159(2):164-7. PubMed ID: 15899391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A study on the incidence of ABL gene deletion on derivative chromosome 9 in chronic myelogenous leukemia by interphase fluorescence in situ hybridization and its association with disease progression.
    Lee DS; Lee YS; Yun YS; Kim YR; Jeong SS; Lee YK; She CJ; Yoon SS; Shin HR; Kim Y; Cho HI
    Genes Chromosomes Cancer; 2003 Jul; 37(3):291-9. PubMed ID: 12759927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Down-regulation of miR-199b associated with imatinib drug resistance in 9q34.1 deleted BCR/ABL positive CML patients.
    Joshi D; Chandrakala S; Korgaonkar S; Ghosh K; Vundinti BR
    Gene; 2014 Jun; 542(2):109-12. PubMed ID: 24680705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib induces a cytogenetic response in blast crisis or interferon failure chronic myeloid leukemia patients with e19a2 BCR-ABL transcripts.
    Lee JJ; Kim HJ; Kim YJ; Lee S; Hwang JY; Kim YL; Kim DW
    Leukemia; 2004 Sep; 18(9):1539-40. PubMed ID: 15284852
    [No Abstract]   [Full Text] [Related]  

  • 14. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
    Cortes J; Talpaz M; O'Brien S; Jones D; Luthra R; Shan J; Giles F; Faderl S; Verstovsek S; Garcia-Manero G; Rios MB; Kantarjian H
    Clin Cancer Res; 2005 May; 11(9):3425-32. PubMed ID: 15867244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clonal evolution with double Ph followed by tetraploidy in imatinib-treated chronic myeloid leukemia with e19a2 transcript in transformation.
    Oshikawa G; Kurosu T; Arai A; Murakami N; Miura O
    Cancer Genet Cytogenet; 2010 May; 199(1):56-61. PubMed ID: 20417871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
    Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND
    Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients.
    Bianchini M; De Brasi C; Gargallo P; Gonzalez M; Bengió R; Larripa I
    Eur J Haematol; 2009 Apr; 82(4):292-300. PubMed ID: 19191867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
    Wei Y; Hardling M; Olsson B; Hezaveh R; Ricksten A; Stockelberg D; Wadenvik H
    Ann Hematol; 2006 Dec; 85(12):841-7. PubMed ID: 17006667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promyelocytic blast crisis of chronic myelogenous leukemia during imatinib treatment.
    Gozzetti A; Bocchia M; Calabrese S; Pirrotta MT; Crupi R; Raspadori D; Lauria F
    Acta Haematol; 2007; 117(4):236-7. PubMed ID: 17308370
    [No Abstract]   [Full Text] [Related]  

  • 20. [Application of interphase fluorescence in situ hybridization for determination of the tumor load in chronic myeloid leukemia].
    Du QF; Zhou SY; Liu XL; Song LL; Zhang Y
    Ai Zheng; 2003 Jun; 22(6):612-5. PubMed ID: 12948411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.